Ilomedin (Iloprost Trometamol)

Iloprost Trometamol acts as an agonist at prostacyclin (IP) receptors on vascular smooth‑muscle cells. Activation of these receptors raises cyclic AMP levels, causing vasodilation of pulmonary and systemic arteries and inhibiting platelet aggregation, which together improve blood flow in affected vessels.

The dose of Ilomedin is individualized by the prescribing clinician based on the patient’s disease severity, response to therapy, and tolerance. Dosing regimens are adjusted according to clinical monitoring of hemodynamic parameters and adverse‑effect profile.

Safety data for Ilomedin in pregnancy and lactation are limited. It is classified as having an unknown pregnancy category, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus. Breastfeeding decisions should be made in consultation with a healthcare professional.

To order Ilomedin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Ilomedin (iloprost trometamol) is a synthetic prostacyclin analog administered intravenously, offering rapid onset of vasodilation. Compared with inhaled or oral prostacyclin agents, it provides more controlled systemic exposure but requires infusion equipment and careful monitoring for hypotension and bleeding.

Ilomedin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if required for infusion, and inspect for particulate matter or discoloration.

Ilomedin is given as an intravenous infusion. The prescribing clinician determines the infusion rate and duration, which are typically titrated based on blood pressure response and tolerance. Infusion sets and sterile techniques must be used according to institutional protocols.

The most serious risks include severe hypotension, pulmonary edema, significant bleeding, thrombocytopenia, and cardiac arrhythmias. These events require immediate medical attention and may necessitate discontinuation of therapy.

Ilomedin is contraindicated in patients with active uncontrolled bleeding, severe hypotension, known hypersensitivity to iloprost or any formulation component, and in those where the risk of vasodilation outweighs potential benefit, such as certain unstable cardiac conditions.